Bispecific Antibodies Market by Therapeutic Area, Mechanism of Action Target Antigen, Antibody Format, Key Geographical Regions and Key Players: Industry Trends and Global Forecasts, Till 2035

As per Roots Analysis, the global bispecific antibodies market is estimated to grow from USD 5.6 billion in the current year to USD 16.8 billion by 2035, at a CAGR of 9.5% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Therapeutic Area

Autoimmune Disorders
Genetic Disorders
Hematological Malignancies
Ophthalmic Disorders
Skin Cancers
Solid Tumors

Mechanism of Action

Cytokines Retargeting / Neutralization
Dual Ligands Blocking
Resistance Factors Co-targeting
Targeting Tumor Angiogenesis
T-Cell Retargeting / Activation
Others

Target Antigen

C5-Albumin
CD20 x CD3
CD3 x BCMA
CD3 x CD19
EGFR x cMET
EpCAM x CD3
Factor IXa x Factor X
gp100 x CD3
HER2 x HER2
PD-1 x CTLA-4
PD-L1 x TGFB
TNF-a x HSA
VEGF x DLL4
VEGF-A x ANG2

Antibody Format

Asymmetric
Fragments

Geography

North America (US, Canada, Rest of North America)
Europe (Germany, France, Italy, Spain, UK, Rest of Europe)
Asia (India, China, Japan, South Korea, Rest of Asia)
Rest of the World

BISPECIFIC ANTIBODIES MARKET: GROWTH AND TRENDS

The discovery of the therapeutic potential of monoclonal antibodies and its successful implementation in the treatment of myriads of diseases has revolutionized the pharmaceutical industry. Presently, significant research is being carried out into engineering antibody therapeutics to further improve treatment-related outcomes. A few decades ago, bispecific antibodies were first developed by the incorporation of additional antigen binding sites into monoclonal antibodies. The primary objective of such bivalent molecules has, so far, been to redirect cytotoxic immune effector cells for augmenting the killing of tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and other cytotoxic mechanisms mediated by the immune effector cells. This modified form of antibody-based therapeutics is currently gaining a lot of attention from both large and small pharmaceutical companies. In the recent past, clinical trials have demonstrated enormous benefits offered by novel bispecific antibody therapeutics for the treatment of a wide range of target indications, presenting lucrative opportunities for the players engaged in the development of these therapies.

BISPECIFIC ANTIBODIES MARKET: KEY INSIGHTS

The report delves into the current state of the bispecific antibodies market and identifies potential growth opportunities within the industry. Some key findings from the report include:

The landscape of bispecific antibody therapeutics has steadily evolved in the past decade; over 400 clinical / preclinical candidates are being evaluated by over 120 drug developers worldwide.

The current pipeline features a number of clinical stage bispecific antibody drug candidates, capable of targeting a range of biological antigens in order to potentially treat multiple target indications.
In fact, industry stakeholders are engaged in the development of over 85 bispecific antibody technology platforms, aiming to mitigate the existing manufacturing challenges associated with such therapies.
The growing interest is evident from the rise in partnership activity; companies are actively entering into strategic agreements in order to expand their bispecific antibody portfolio.
Since 2010, nearly 280 clinical trials have been registered to evaluate the safety and efficacy of various bispecific antibody therapeutics; majority of these studies are being conducted across sites in the US.
In order to efficiently promote these therapies, drug developers are actively exploring diverse promotional strategies with an aim to sustain their position in the market.
With the growing focus on development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 9.5%, during the next decade.

BISPECIFIC ANTIBODIES MARKET: KEY SEGMENTS

Hematological Malignancies are the Fastest Growing Segment of the Bispecific Antibodies Market During the Forecast Period

Based on the therapeutic area, the market is segmented into autoimmune disorders, genetic disorders, hematological malignancies, ophthalmic disorders, skin cancers and solid tumors. At present, genetic disorders hold the maximum share of the bispecific antibodies market. It is worth highlighting that the bispecific antibodies market for hematological malignancies is likely to grow at a relatively higher CAGR.

Bispecific Antibodies Acting Through T-Cell Retargeting / Activation Occupy the Largest Share of the Bispecific Antibodies Market

Based on the mechanism of action, the market is segmented into cytokines retargeting / neutralization, dual ligands blocking, resistance factors co-targeting, targeting tumor angiogenesis, T-cell retargeting / activation and others. Currently, T-cell retargeting / activation holds the maximum share of the bispecific antibodies market. However, bispecific antibodies acting through cytokines retargeting / neutralization are anticipated to capture the highest market in the near future.

Bispecific Antibodies Targeting CD3 x BCMA is the Fastest Growing Segment of the Market During the Forecast Period

Based on target antigen, the market is segmented into C5-Albumin, CD20 x CD3, CD3 x BCMA, CD3 x CD19, EGFR x cMET, EpCAM x CD3, Factor IXa x Factor X, gp100 x CD3, HER2 x HER2, PD-1 x CTLA-4, PD-L1 x TGFB, TNF-a x HSA, VEGF x DLL4 and VEGF-A x ANG2. At present, therapies targeting factor IXa x factor X holds the maximum share of the bispecific antibodies market. It is worth highlighting that the drugs intended to target CD3 x BCMA are likely to grow at a relatively higher CAGR.

Asymmetric Bispecific Antibodies are Likely to Dominate the Bispecific Antibodies Market During the Forecast Period

Based on the antibody format, the market is segmented into asymmetric and fragments. Currently, asymmetric antibodies hold the maximum share of the bispecific antibodies market. This trend is unlikely to change in the foreseeable future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Bispecific Antibodies Market

Akeso Biopharma
Alexion
Amgen
Genmab
Immunocore
Janssen Research & Development
Linton Pharm
Merck
OncXerna Therapeutics
Pfizer
Roche
Taisho Pharmaceutical
Zymeworks

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Senior Scientist, Immunai
Business Development Consultant, F-star
Director (GMP Clinical Manufacturing), Innovent Biologics
Former Senior Director, Business Development, CytomX Therapeutics
Founder and Chief Scientific Officer and Chief Executive Officer, SYNIMMUNE
PhD Student, University of Freiburg

BISPECIFIC ANTIBODIES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bispecific antibodies market, focusing on key market segments, including [A] therapeutic area, [B] mechanism of action, [C] target antigen, [D] antibody format and [E] Key geographical regions.
Market Landscape 1: A comprehensive evaluation of bispecific antibodies that are either approved or being evaluated in different stages of clinical development, considering various parameters, such as [A] developer company, [B] phase of development, [C] target antigen, [D] type of therapy, [E] route of administration, [F] method of administration, [G] target indication, [H] therapeutic area, [I] disease segment, [J] year of establishment, [K] company size and [L] location of headquarter.
Market Landscape 2: A comprehensive evaluation of bispecific antibodies that are currently being evaluated in preclinical studies, considering various parameters, such as [A] developer company, [B] stage of development, [C] target antigen, [D] therapeutic area, [E] disease segment, [F] year of establishment, [G] company size and [H] location of headquarters of the developer.
Key Insights: A detailed analysis, encompassing the contemporary bispecific antibody therapeutics market trends, based on relevant parameters, such as [A] phase of development and route of administration, [B] phase of development and disease segment, and [C] phase of development and location of their headquarters. In addition, this chapter includes various representations of preclinical stage bispecific antibody therapeutics based on [D] stage of development and disease segment, and [E] stage of development and location of their headquarters. Further, the chapter also includes representation of the developers of bispecific antibody therapeutics based on [F] stage of development (preclinical, clinical and preclinical and clinical) of their drug candidates and [G] location of their headquarters.
Technology Assessment Framework: A detailed assessment of technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics, based on multiple relevant parameters, such as [A] clinical / preclinical pipeline strength, [B] developer's years of experience, [C] company size and [D] location of headquarters of developers.
Big Pharma Analysis: A comprehensive examination of various initiatives focused on bispecific antibody therapeutics undertaken by major pharmaceutical companies. This analysis includes heat map visualizations that illustrate the distribution of leading pharmaceutical firms, as well as spider web diagrams that compare their initiatives across multiple relevant parameters.
Company Profiles: In-depth profiles of key industry players engaged in the development of bispecific antibodies across various geographies, focusing on [A] company overviews, [B] financial information (if available), [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2016, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] disease segment, [D] type of payment model employed, [E] deal amount, [F] most active players (in terms of number of deals inked), [G] most popular technologies (in terms of number of deals inked for technologies). This section also highlights the regional distribution of partnership activity in this market.
Contract Services for Bispecific Antibody Therapeutics: A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, this section includes a list of contract manufacturing organizations (CMOs) and biologics contract research organization (CROs), highlighting the key considerations for bispecific antibody developers, while selecting a suitable CRO / CMO.
Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various bispecific antibody therapeutics based on parameters like [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] enrolled patient population, [E] type of study, [F] study design, [G] type of sponsor / collaborator, [H] leading industry and non-industry players, [I] key focus areas and [J] geographical location of trials.
Case Study 1: A discussion on general regulatory guidelines issued by the ICH, WHO and FDA for the development of bispecific antibodies. In addition, it provides details related to the responses of various pharmaceutical industries to the FDA guidelines.
Case Study 2: A review of different channels used for promoting marketed bispecific antibodies , along with examples of players that have undertaken such initiatives, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies, namely Blincyto(R) and Hemlibra(R), and comparison of both the drugs based on information available on their respective websites.
SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry's evolution. Further, it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100434

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Introduction to Antibodies
- 3.2.1. Structure
- 3.2.2. Functions
- 3.2.3. Mechanism of Action
3.3. Antibody Therapeutics
- 3.3.1. Historical Evolution of Antibody Therapeutics
- 3.3.2. Key Approved Antibody Therapeutics
- 3.3.3. Advanced Antibody Therapeutics
  - 3.3.3.1. Fc Engineered and Glycoengineered Antibodies
  - 3.3.3.2. Antibody Fragments
  - 3.3.3.3. Fusion Proteins
  - 3.3.3.4. Intrabodies
  - 3.3.3.5. Bispecific Antibodies
3.4. Bispecific Antibody Formats
- 3.4.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
  - 3.4.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
  - 3.4.1.2. Bispecific Single-Domain Antibody Fusion Proteins
  - 3.4.1.3. Diabodies / Diabody Derivatives
  - 3.4.1.4. Fusion Proteins
  - 3.4.1.5. Fusion Proteins Devoid of Fc Regions
- 3.4.2. Immunoglobulin G Based Formats (Fc Dependent Antibody Formats)
  - 3.4.2.1. Quadromas
  - 3.4.2.2. Knobs-Into-Holes
  - 3.4.2.3. Dual Variable Domain Ig
  - 3.4.2.4. IgG-scFv
  - 3.4.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
  - 3.4.2.6. Half Molecule Exchange
  - 3.4.2.7. κλ- Bodies
3.5. Mechanism of Action of Bispecific Antibody Therapeutics
- 3.5.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
- 3.5.2. Directly Targeting Malignant / Tumor Cells
- 3.5.3. Retargeting of Toxins
- 3.5.4. Targeting Tumor Angiogenesis
- 3.5.5. Other Mechanisms
3.6. Applications of Bispecific Antibodies

4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES

4.1. Chapter Overview
4.2. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Target Antigen
- 4.2.3. Analysis by Type of Therapy
- 4.2.4. Analysis by Route of Administration
- 4.2.5. Analysis by Method of Administration
- 4.2.6. Analysis by Target Indication
- 4.2.7. Analysis by Therapeutic Area
- 4.2.8. Analysis by Disease Segment
4.3. Approved and Clinical Bispecific Antibody Therapeutics: Overall Developer Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters

5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES

5.1. Chapter Overview
5.2. Preclinical Bispecific Antibody Therapeutics: Overall Market Landscape
- 5.2.1. Analysis by Stage of Development
- 5.2.2. Analysis by Target Antigen
- 5.2.3. Analysis by Therapeutic Area and Disease Segment
5.3. Preclinical Bispecific Antibody Therapeutics: Overall Developer Landscape
- 5.3.1. Analysis by Year of Establishment
- 5.3.2. Analysis by Company Size
- 5.3.3. Analysis by Location of Headquarters

6. KEY INSIGHTS

6.1. Chapter Overview
6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
- 6.2.1. Analysis by Phase of Development and Route of Administration
- 6.2.2. Analysis by Phase of Development and Disease Segment
- 6.2.3. Analysis by Phase of Development and Location of Developer's Headquarters
6.3. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
- 6.3.1. Analysis by Stage of Development and Therapeutic Area
- 6.3.2. Analysis by Stage of Development and Location of Developer Headquarters
6.4. Bispecific Antibody Therapeutic Developers Landscape: Key Insights
- 6.4.1. Distribution by Stage of Development
- 6.4.2. Distribution by Stage of Development and Region of Developer Headquarters

7. TECHNOLOGY ASSESSMENT FRAMEWORK

7.1. Chapter Overview
7.2. Bispecific Antibody Therapeutics: List of Technology Platforms
7.3. Bispecific Antibody Technology Platforms: Comparative Analysis
- 7.3.1. Analysis by Technologies for Approved and Clinical Drugs
- 7.3.2. Analysis by Technologies for Preclinical Drugs
7.4. Most Popular Technology Platforms: Analysis by Stage of Development
7.5. Bispecific Antibody Technology Platform Developers: Analysis by Location of Headquarters

8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS

8.1. Chapter Overview
8.2. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)
8.3. Big Pharma Players: Comparative Clinical Pipeline Analysis
- 8.3.1. Analysis by Target Antigen
- 8.3.2. Analysis by Antibody Format
- 8.3.3. Analysis by Mechanism of Action
- 8.3.4. Analysis by Therapeutic Area

9. COMPANY PROFILES

9.1. Chapter Overview
9.2. Akeso Biopharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Drug Portfolio
- 9.2.4. Recent Developments and Future Outlook
9.3. Alphamab Oncology
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Drug Portfolio
- 9.3.4. Recent Developments and Future Outlook
9.4. Amgen
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Drug Portfolio
- 9.4.4. Recent Developments and Future Outlook
9.5. Merck
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Drug Portfolio
- 9.5.4. Recent Developments and Future Outlook
9.6. Regeneron
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Drug Portfolio
- 9.6.4. Recent Developments and Future Outlook
9.7. Roche
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Drug Portfolio
- 9.7.4. Recent Developments and Future Outlook
9.8. Xencor
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Drug Portfolio
- 9.8.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Disease Segment
- 10.3.5. Analysis by Type of Payment Model Employed and Deal Amount
- 10.3.6. Analysis by Year of Agreement, Type of Payment Model Employed and Deal Amount
- 10.3.7. Analysis by Disease Segment, Type of Payment Model Employed and Deal Amount
- 10.3.8. Most Active Players: Analysis by Number of Partnership Instances
- 10.3.9. Most Popular Technologies: Analysis by Number of Partnership Instances
- 10.3.10. Analysis by Region
- 10.3.11. Intercontinental and Intracontinental Agreements

11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS

11.1. Chapter Overview
11.2. Manufacturing of Bispecific Antibody Therapeutics
- 11.2.1. Key Considerations for Manufacturing and Associated Challenges
- 11.2.2. Contract Manufacturing Organizations (CMOs)
  - 11.2.2.1. Bispecific Antibody Therapeutics: List of CMOs
- 11.2.3. Contract Research Organizations (CROs)
  - 11.2.3.1. Bispecific Antibody Therapeutics: List of CROs
11.3. Key Considerations for Selecting a Suitable CMO / CRO Partner

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis
- 12.3.1. Analysis by Trial Registration Year
- 12.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
- 12.3.3. Analysis by Trial Phase
- 12.3.4. Analysis of Enrolled Patient Population by Trial Phase
- 12.3.5. Analysis by Trial Recruitment Status
- 12.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
- 12.3.7. Analysis by Type of Study
- 12.3.8. Analysis by Study Design
- 12.3.9. Analysis by Type of Sponsor / Collaborator
- 12.3.10. Leading Industry Players: Analysis by Number of Registered Trials
- 12.3.11. Leading Non-Industry Players: Analysis by Number of Registered Trials
- 12.3.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
- 12.3.13. Analysis by Geography
- 12.3.14. Analysis by Trial Recruitment Status and Geography
- 12.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES

13.1. Chapter Overview
13.2. Guidelines Issued by Regulatory Authorities
- 13.2.1. US Food and Drug Administration (FDA)
  - 13.2.1.1. Pharma Companies' Response to the FDA Draft Guidance
- 13.2.2. World Health Organization (WHO)

14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

14.1. Chapter Overview
14.2. Key Channels Used for Promotional Campaigns
- 14.2.1. Product Websites
- 14.2.2. Patient Assistance Programs
- 14.2.3. Participation in Conferences
- 14.2.4. Collaboration with Stakeholders
- 14.2.5. Drug Approval Across Multiple Geographies
14.3. Other Channels Used for Promotional and Marketing Strategies
14.4. Summary: Promotional and Marketing Strategy Leveraged by Bispecific

Antibody Developers

14.5. Promotional Analysis: Blincyto(R)
- 14.5.1. Drug Overview
- 14.5.2. Product Website analysis
  - 14.5.2.1. Messages for Healthcare Professionals
    - 14.5.2.1.1. For MRD Positive B cell precursor ALL
    - 14.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL
  - 14.5.2.2. Messages for Patients
- 14.5.3. Patient Support Services and Informative Downloads
- 14.5.4. Other Promotional Strategies
  - 14.5.4.1. Presence in Conferences
14.6. Promotional Analysis: Hemlibra(R)
- 14.6.1. Drug Overview
- 14.6.2. Product Website Analysis
  - 14.6.2.1. Messages for Healthcare Professionals
    - 14.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
    - 14.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
  - 14.6.2.2. Messages for Patients
- 14.6.3. Patient Support Services and Informative Downloads
  - 14.6.3.1. Co-pay Program
  - 14.6.3.2. Independent Co-pay Assistance Foundation
  - 14.6.3.3. Genentech Patient Foundation
- 14.6.4. Other Promotional Strategies
  - 14.6.4.1. Presence in Conferences

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology and Key Assumptions
15.4. Bispecific Antibody Therapeutics Market, till 2035
- 15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area, Current Year and 2035
- 15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action, Current Year and 2035
- 15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Target Antigen, Current Year and 2035
- 15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Format, Current Year and 2035
- 15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players, Current Year and 2035
- 15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Geography, Current Year and 2035
15.5. Bispecific Antibody Market: Value Creation Analysis
15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts
- 15.6.1. AK104 (Akeso Biopharma)
  - 15.6.1.1. Target Patient Population
  - 15.6.1.2. Sales Forecast
  - 15.6.1.3. Net Present Value
  - 15.6.1.4. Value Creation Analysis
- 15.6.2. Blincyto(TM) (Amgen)
  - 15.6.2.1. Target Patient Population
  - 15.6.2.2. Sales Forecast
  - 15.6.2.3. Net Present Value
  - 15.6.2.4. Value Creation Analysis
- 15.6.3. Hemlibra(R) (Roche)
  - 15.6.3.1. Target Patient Population
  - 15.6.3.2. Sales Forecast
  - 15.6.3.3. Net Present Value
  - 15.6.3.4. Value Creation Analysis
- 15.6.4. Kimmtrak(R) (Immunocore)
  - 15.6.4.1. Target Patient Population
  - 15.6.4.2. Sales Forecast
  - 15.6.4.3. Net Present Value
  - 15.6.4.4. Value Creation Analysis
- 15.6.5. Lunsumio(R) (Roche)
  - 15.6.5.1. Target Patient Population
  - 15.6.5.2. Sales Forecast
  - 15.6.5.3. Net Present Value
  - 15.6.5.4. Value Creation Analysis
- 15.6.6. Nanozora(R) (Taisho Pharmaceutical)
  - 15.6.6.1. Target Patient Population
  - 15.6.6.2. Sales Forecast
  - 15.6.6.3. Net Present Value
  - 15.6.6.4. Value Creation Analysis
- 15.6.7. Rybrevant(TM) (Janssen Research & Development)
  - 15.6.7.1. Target patient Population
  - 15.6.7.2. Sales Forecast
  - 15.6.7.3. Net Present Value
  - 15.6.7.4. Value Creation Analysis
- 15.6.8. Tecvayli(TM) (Janssen Research & Development)
  - 15.6.8.1. Target Patient Population
  - 15.6.8.2. Sales Forecast
  - 15.6.8.3. Net Present Value
  - 15.6.8.4. Value Creation Analysis
- 15.6.9. Vabysmo(TM) (Roche)
  - 15.6.9.1. Target Patient Population
  - 15.6.9.2. Sales Forecast
  - 15.6.9.3. Net Present Value
  - 15.6.9.4. Value Creation Analysis
- 15.6.10. AK112 (Akeso Biopharma)
  - 15.6.10.1. Target Patient Population
  - 15.6.10.2. Sales Forecast
  - 15.6.10.3. Net Present Value
  - 15.6.10.4. Value Creation Analysis
- 15.6.11. ALXN1720 (Alexion)
  - 15.6.11.1. Target Patient Population
  - 15.6.11.2. Sales Forecast
  - 15.6.11.3. Net Present Value
  - 15.6.11.4. Value Creation Analysis
- 15.6.12. GEN3013 (Genmab)
  - 15.6.12.1. Target Patient Population
  - 15.6.12.2. Sales Forecast
  - 15.6.12.3. Net Present Value
  - 15.6.12.4. Value Creation Analysis
- 15.6.13. Glofitamab (Roche)
  - 15.6.13.1. Target Patient Population
  - 15.6.13.2. Sales Forecast
  - 15.6.13.3. Net Present Value
  - 15.6.13.4. Value Creation Analysis
- 15.6.14. LP000 (Linton Pharm)
  - 15.6.14.1. Target Patient Population
  - 15.6.14.2. Sales Forecast
  - 15.6.14.3. Net Present Value
  - 15.6.14.4. Value Creation Analysis
- 15.6.15. M7824 (Merck)
  - 15.6.15.1. Target Patient Population
  - 15.6.15.2. Sales Forecast
  - 15.6.15.3. Net Present Value
  - 15.6.15.4. Value Creation Analysis
- 15.6.16. OMP 305B83 (Mereo BioPharma)
  - 15.6.16.1. Target Patient Population
  - 15.6.16.2. Sales Forecast
  - 15.6.16.3. Net Present Value
  - 15.6.16.4. Value Creation Analysis
- 15.6.17. PF-06863135 (Pfizer)
  - 15.6.17.1. Target Patient Population
  - 15.6.17.2. Sales Forecast
  - 15.6.17.3. Net Present Value
  - 15.6.17.4. Value Creation Analysis
- 15.6.18. ZW25 (Zymeworks)
  - 15.6.18.1. Target Patient Population
  - 15.6.18.2. Sales Forecast
  - 15.6.18.3. Net Present Value
  - 15.6.18.4. Value Creation Analysis
15.7. Concluding Remarks

16. SWOT ANALYSIS

16.1. Chapter Overview
16.2. Strengths
- 16.2.1. Enhanced Specificity
- 16.2.2. Diverse Application Areas
- 16.2.3. Lower Drug Resistance
- 16.2.4. Success of Approved Products
16.3. Weaknesses
- 16.3.1. Uncertainties with Safety of Therapeutic Candidates
- 16.3.2. Complex Purification and Downstream Processing
- 16.3.3. Dimerization in Antibodies with Fc-region
16.4. Opportunities
- 16.4.1. Life Cycle Management of Novel Therapies
- 16.4.2. Growing Number of High Value Partnerships
- 16.4.3. Expertise Available with Contract Manufacturing Organizations
- 16.4.4. Emergence of Advanced Technologies
16.5. Threats
- 16.5.1. Rise in Attrition Rate of Clinical Stage Candidates
16.6. Concluding Remarks

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

18.1. Chapter Overview
18.2. Immunai
- 18.2.1. Company Snapshot
- 18.2.2. Interview Transcript: Senior Scientist
18.3. University of Freiburg
- 18.3.1. Company Snapshot
- 18.3.2. Interview Transcript: PhD Student
18.4. SYNIMMUNE
- 18.4.1. Company Snapshot
- 18.4.2. Interview Transcript: Founder and Chief Scientific Officer, and Chief Executive Officer
18.5. CytomX Therapeutics
- 18.5.1. Company Snapshot
- 18.5.2. Interview Transcript: Former Senior Director, Business Development
18.6. F-star
- 18.6.1. Company Snapshot
- 18.6.2. Interview Transcript: Business Development Consultant
18.7. Innovent Biologics
- 18.7.1. Company Snapshot
- 18.7.2. Interview Transcript: Director, GMP Clinical Manufacturing

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

Product Code: RA100434

List of Tables

Table 3.1. Isotypes of Mammalian Antibodies
Table 3.2. Mechanisms of Action of Antibody Therapeutics
Table 3.3. Revenue of Top Antibody Therapeutics (USD Billion)
Table 4.1. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Developer(s), Phase of Development and Target Antigen
Table 4.2. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Type of Therapy, Route of Administration and Method of Administration
Table 4.3. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Target Indication(s), Therapeutic Area(s) and Disease Segment(s)
Table 4.4. Bispecific Antibody Therapeutic Developers: Information on Approved and Clinical Drug Candidates Developers, Year of Establishment, Company Size, Location of Headquarters
Table 5.1. Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidates, Developer(s), Stage of Development and Target Antigen
Table 5.2. Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidates, Developer(s), Therapeutic Area(s) and Disease Segment(s)
Table 5.3. Bispecific Antibody Therapeutic Developers: Information on Preclinical Drug Candidates Developers, Year of Establishment, Company Size, Location of Headquarters
Table 7.1. Bispecific Antibody Therapeutics: List of Technology Platforms
Table 9.1. Bispecific Antibody Therapeutic Developers: List of Companies Profiled
Table 9.2. Akeso Biopharma: Company Overview
Table 9.3. Akeso Biopharma: Bispecific Antibody Therapeutics Portfolio
Table 9.4. Akeso Biopharma: Recent Developments and Future Outlook
Table 9.5. Alphamab Oncology: Company Overview
Table 9.6. Alphamab Oncology: Bispecific Antibody Therapeutics Portfolio
Table 9.7. Alphamab Oncology: Recent Developments and Future Outlook
Table 9.8. Amgen: Company Overview
Table 9.9. Amgen: Bispecific Antibody Therapeutics Portfolio
Table 9.10. Amgen: Recent Developments and Future Outlook
Table 9.11. Merck: Company Overview
Table 9.12. Merck: Bispecific Antibody Therapeutics Portfolio
Table 9.13. Merck: Recent Developments and Future Outlook
Table 9.14. Regeneron: Company Overview
Table 9.15. Regeneron: Bispecific Antibody Therapeutics Portfolio
Table 9.16. Regeneron: Recent Developments and Future Outlook
Table 9.17. Roche: Company Overview
Table 9.18. Roche: Bispecific Antibody Therapeutics Portfolio
Table 9.19. Roche: Recent Developments and Future Outlook
Table 9.20. Xencor: Company Overview
Table 9.21. Xencor: Bispecific Antibody Therapeutics Portfolio
Table 9.22. Xencor: Recent Developments and Future Outlook
Table 10.1. Partnerships and Collaborations: Information on Year of Agreement, Partner and Type of Agreement, since 2016
Table 10.2. Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), since 2016
Table 11.1. List of Bispecific Antibody CMOs: Company Specifications
Table 11.2. List of Bispecific Antibody CMOs: Information on Scale of Operation
Table 11.3. List of Bispecific Antibody CROs: Company Specifications
Table 11.4. List of Bispecific Antibody CROs: Information on Type of Service
Table 11.5. Comparison of Key Factors for the Selection of Contract Service Provider: Harvey Ball Analysis
Table 14.1. List of Bispecific Antibodies Approved Across Various Geographies
Table 15.1. Bispecific Antibody Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
Table 15.2. AK104: Target Patient Population
Table 15.3. AK104: Net Present Value (USD Million)
Table 15.4. AK104: Value Creation Analysis (USD Million)
Table 15.5. Blincyto(R): Target Patient Population
Table 15.6. Blincyto(R): Net Present Value (USD Million)
Table 15.7. Blincyto(R): Value Creation Analysis (USD Million)
Table 15.8. Hemlibra(R): Target Patient Population
Table 15.9. Hemlibra(R): Net Present Value (USD Million)
Table 15.10. Hemlibra(R): Value Creation Analysis (USD Million)
Table 15.11. Kimmtrak(R): Target Patient Population
Table 15.12. Kimmtrak(R): Net Present Value (USD Million)
Table 15.13. Kimmtrak(R): Value Creation Analysis (USD Million)
Table 15.14. Lunsumio(R): Target Patient Population
Table 15.15. Lunsumio(R): Net Present Value (USD Million)
Table 15.16. Lunsumio(R): Value Creation Analysis (USD Million)
Table 15.17. Nanozora(R): Target Patient Population
Table 15.18. Nanozora(R): Net Present Value (USD Million)
Table 15.19. Nanozora(R): Value Creation Analysis (USD Million)
Table 15.20. Rybrevant(TM): Target Patient Population
Table 15.21. Rybrevant(TM): Net Present Value (USD Million)
Table 15.22. Rybrevant(TM): Value Creation Analysis (USD Million)
Table 15.23. Tecvayli(TM): Target Patient Population
Table 15.24. Tecvayli(TM): Net Present Value (USD Million)
Table 15.25. Tecvayli(TM): Value Creation Analysis (USD Million)
Table 15.26. Vabysmo(TM): Target Patient Population
Table 15.27. Vabysmo(TM): Net Present Value (USD Million)
Table 15.28. Vabysmo(TM): Value Creation Analysis (USD Million)
Table 15.29. AK112: Target Patient Population
Table 15.30. AK112: Net Present Value (USD Million)
Table 15.31. AK112: Value Creation Analysis (USD Million)
Table 15.32. ALXN1720: Target Patient Population
Table 15.33. ALXN1720: Net Present Value (USD Million)
Table 15.34. ALXN1720: Value Creation Analysis (USD Million)
Table 15.35. GEN3013: Target Patient Population
Table 15.36. GEN3013: Net Present Value (USD Million)
Table 15.37. GEN3013: Value Creation Analysis (USD Million)
Table 15.38. Glofitamab: Target Patient Population
Table 15.39. Glofitamab: Net Present Value (USD Million)
Table 15.40. Glofitamab: Value Creation Analysis (USD Million)
Table 15.41. LP000: Target Patient Population
Table 15.42. LP000: Net Present Value (USD Million)
Table 15.43. LP000: Value Creation Analysis (USD Million)
Table 15.44. M7824: Target Patient Population
Table 15.45. M7824: Net Present Value (USD Million)
Table 15.46. M7824: Value Creation Analysis (USD Million)
Table 15.47. OMP 305B83: Target Patient Population
Table 15.48. OMP 305B83: Net Present Value (USD Million)
Table 15.49. OMP 305B83: Value Creation Analysis (USD Million)
Table 15.50. PF-06863135: Target Patient Population
Table 15.51. PF-06863135: Net Present Value (USD Million)
Table 15.52. PF-06863135: Value Creation Analysis (USD Million)
Table 15.53. ZW25: Target Patient Population
Table 15.54. ZW25: Net Present Value (USD Million)
Table 15.55. ZW25: Value Creation Analysis (USD Million)
Table 18.1. Immunai: Company Snapshot
Table 18.2. University of Freiburg: Organization Snapshot
Table 18.3. SYNIMMUNE: Company Snapshot
Table 18.4. CytomX Therapeutics: Company Snapshot
Table 18.5. F-star: Company Snapshot
Table 18.6. Innovent Biologics: Company Snapshot
Table 19.1. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 19.2. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Table 19.3. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Type of Therapy
Table 19.4. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Route of Administration
Table 19.5. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Method of Administration
Table 19.6. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Table 19.7. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Table 19.8. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Table 19.9. Approved and Clinical Bispecific Antibody Therapeutic Developers: Distribution by Year of Establishment
Table 19.10. Approved and Clinical Bispecific Antibody Therapeutic Developers: Distribution by Company Size
Table 19.11. Approved and Clinical Bispecific Antibody Therapeutic Developers: Distribution by Location of Headquarters
Table 19.12. Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Table 19.13. Preclinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Table 19.14. Preclinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Table 19.15. Preclinical Bispecific Antibody Therapeutic Developers: Distribution by Year of Establishment
Table 19.16. Preclinical Bispecific Antibody Therapeutic Developers: Distribution by Company Size
Table 19.17. Preclinical Bispecific Antibody Therapeutic Developers: Distribution by Location of Headquarters
Table 19.18. Most Popular Technology Platforms: Distribution by Stage of Development
Table 19.19. Bispecific Antibody Technology Platform Developers: Distribution by Location of Headquarters
Table 19.20. Akeso Biopharma: Annual Revenues, FY 2019 Onwards (RMB Million)
Table 19.21. Alphamab Oncology: Annual Revenues, FY 2019 Onwards (RMB Million)
Table 19.22. Amgen: Annual Revenues, FY 2019 Onwards (USD Billion)
Table 19.23. Merck: Annual Revenues, FY 2019 Onwards (EUR Billion)
Table 19.24. Regeneron: Annual Revenues, FY 2019 Onwards (USD Billion)
Table 19.25. Roche: Annual Revenues, FY 2019 Onwards (CHF Million)
Table 19.26. Xencor: Annual Revenues, FY 2019 Onwards (USD Million)
Table 19.27. Partnerships and Collaborations: Cumulative Year-wise Trend, since 2016
Table 19.28. Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.29. Partnerships and Collaborations: Distribution by Disease Segment
Table 19.30. Partnerships and Collaborations: Distribution by Type of Payment Model Employed and Deal Amount (USD Billion)
Table 19.31. Partnerships and Collaborations: Year-wise Distribution by Type of Payment Model Employed and Deal Amount (USD Billion, since 2016)
Table 19.32. Partnerships and Collaborations: Distribution by Disease Segment, Type of Payment Model Employed and Deal Amount (USD Billion)
Table 19.33. Most Active Players: Distribution by Number of Partnership Instances
Table 19.34. Most Popular Technologies: Distribution by Number of Partnership Instances
Table 19.35. Partnerships and Collaborations: Distribution by Region
Table 19.36. Partnerships and Collaborations: International and Intracontinental Agreements
Table 19.37. Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year
Table 19.38. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 19.39. Clinical Trial Analysis: Distribution by Trial Phase
Table 19.40. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.41. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 19.42. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 19.43. Clinical Trial Analysis: Distribution by Type of Study
Table 19.44. Clinical Trial Analysis: Distribution by Study Design
Table 19.45. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.46. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 19.47. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Recruitment Status
Table 19.48. Bispecific Antibody Therapeutics Market, Conservative, Base, and Optimistic Scenarios, till 2035 (USD Million)
Table 19.49. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, Conservative, Base, and Optimistic Scenarios, Current Year and 2035 (USD Million)
Table 19.50. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, Conservative, Base, and Optimistic Scenarios, Current Year and 2035 (USD Million)
Table 19.51. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, Conservative, Base, and Optimistic Scenarios, Current Year and 2035 (USD Million)
Table 19.52. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, Conservative, Base, and Optimistic Scenarios, Current Year and 2035 (USD Million)
Table 19.53. Bispecific Antibody Therapeutics Market: Distribution by Key Players, Conservative, Base, and Optimistic Scenarios, Current Year and 2035 (USD Million)
Table 19.54. Bispecific Antibody Therapeutics Market: Distribution by Geography, Conservative, Base, and Optimistic Scenarios, Current Year and 2035 (USD Million)
Table 19.55. AK104 (Akeso Biopharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.56. Blincyto(R) (Amgen) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.57. Hemlibra(R) (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.58. Kimmtrak(R) (Immunocore) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.59. Lunsumio(R) (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.60. Nanozora(R) (Taisho Pharmaceutical) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.61. Rybrevant(TM) (Janssen Research & Development) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.62. Tecvayli(TM) (Janssen Research & Development) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.63. Vabysmo(TM) (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.64. AK112 (Akeso Biopharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.65. ALXN1720 (Alexion) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.66. GEN3013 (Genmab) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.67. Glofitamab (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.68. LP000 (Linton Pharm) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.69. M7824 (Merck) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.70. OMP 305B83 (Mereo BioPharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.71. PF-06863135 (Pfizer) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.72. ZW25 (Zymeworks) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)

List of Figures

Figure 3.1. Historical Evolution of Antibody Therapeutics
Figure 3.2. Basic Structure of an Antibody
Figure 3.3. Revenues of Top 15 Drugs (USD Billion)
Figure 3.4. Symmetric and Asymmetric Bispecific Antibodies
Figure 4.1. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 4.2. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Figure 4.3. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Type of Therapy
Figure 4.4. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Route of Administration
Figure 4.5. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Method of Administration
Figure 4.6. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Figure 4.7. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Figure 4.8. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Figure 4.9. Approved and Clinical Bispecific Antibody Therapeutic Developers: Distribution by Year of Establishment
Figure 4.10. Approved and Clinical Bispecific Antibody Therapeutic Developers: Distribution by Company Size
Figure 4.11. Approved and Clinical Bispecific Antibody Therapeutic Developers: Distribution by Location of Headquarters
Figure 5.1. Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Figure 5.2. Preclinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Figure 5.3. Preclinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Figure 5.4. Preclinical Bispecific Antibody Therapeutic Developers: Distribution by Year of Establishment
Figure 5.5. Preclinical Bispecific Antibody Therapeutic Developers: Distribution by Company Size
Figure 5.6. Preclinical Bispecific Antibody Therapeutic Developers: Distribution by Location of Headquarters
Figure 6.1. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Route of Administration
Figure 6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Disease Segment
Figure 6.3. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Location of Developer Headquarters
Figure 6.4. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Stage of Development and Disease Segment
Figure 6.5. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Stage of Development and Location of Developer Headquarters
Figure 6.6. Bispecific Antibody Therapeutic Developers Landscape: Distribution by Stage of Development
Figure 6.7. Bispecific Antibody Therapeutic Developers Landscape: Distribution by Stage of Development and Region of Developer Headquarters
Figure 7.1. Technology Platforms for Approved and Clinical Bispecific Antibodies: Comparative Analysis
Figure 7.2. Technology Platforms for Preclinical Bispecific Antibodies: Comparative Analysis
Figure 7.3. Most Popular Technology Platforms: Distribution by Stage of Development
Figure 7.4. Bispecific Antibody Technology Platform Developers: Distribution by Location of Headquarters
Figure 8.1. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)
Figure 8.2. Big Pharma Players: Distribution by Target Antigen
Figure 8.3. Big Pharma Players: Distribution by Antibody Format
Figure 8.4. Big Pharma Players: Distribution by Mechanism of Action
Figure 8.5. Big Pharma Players: Distribution by Therapeutic Area
Figure 9.1. Akeso Biopharma: Annual Revenues, FY 2019 Onwards (RMB Million)
Figure 9.2. Alphamab Oncology: Annual Revenues, FY 2019 Onwards (RMB Million)
Figure 9.3. Amgen: Annual Revenues, FY 2019 Onwards (USD Billion)
Figure 9.4. Merck: Annual Revenues, FY 2019 Onwards (EUR Billion)
Figure 9.5. Regeneron: Annual Revenues, FY 2019 Onwards (USD Billion)
Figure 9.6. Roche: Annual Revenues, FY 2019 Onwards (CHF Million)
Figure 9.7. Xencor: Annual Revenues, FY 2019 Onwards (USD Million)
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, since 2016
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4. Partnerships and Collaborations: Distribution by Disease Segment
Figure 10.5. Partnerships and Collaborations: Distribution by Type of Payment Model Employed and Deal Amount (USD Billion)
Figure 10.6. Partnerships and Collaborations: Year-wise Distribution by Type of Payment Model Employed and Deal Amount (USD Billion, since 2016)
Figure 10.7. Partnerships and Collaborations: Distribution by Disease Segment, Type of Payment Model Employed and Deal Amount (USD Billion)
Figure 10.8. Most Active Players: Distribution by Number of Partnership Instances
Figure 10.9. Most Popular Technologies: Distribution by Number of Partnership Instances
Figure 10.10. Partnerships and Collaborations: Distribution by Region
Figure 10.11. Partnerships and Collaborations: International and Intracontinental Agreements
Figure 12.1. Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year
Figure 12.2. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.4. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 12.5. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 12.6. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 12.7. Clinical Trial Analysis: Distribution by Type of Study
Figure 12.8. Clinical Trial Analysis: Distribution by Study Design
Figure 12.9. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.10. Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.11. Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
Figure 12.13. Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 12.14. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 12.15. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Recruitment Status
Figure 13.1. FDA Considerations for Development of Bispecific Antibodies
Figure 14.1. Key Channels Used for Promotional and Marketing Campaigns
Figure 14.2. Blincyto(R): Product Website Snapshots (Messages for Healthcare Professionals, BLAST Study Results)
Figure 14.3. Blincyto(R): Product Website Snapshots (Messages for Healthcare Professionals, TOWER Study Results)
Figure 14.4. Blincyto(R): Product Website Snapshots (Messages for Healthcare Professionals, Ph (+) Relapsed / Refractory B-cell Precursor ALL)
Figure 14.5. Blincyto(R): Product Website Snapshots (Messages for Healthcare Professionals, Relapsed / Refractory B-cell Precursor ALL (Pediatrics))
Figure 14.6. Blincyto(R): Product Website Snapshots (Messages for Patients)
Figure 14.7. Blincyto(R): Amgen Assist 360 Nurse Ambassador
Figure 14.8. Blincyto(R): Presence in Conferences
Figure 14.9. Hemlibra(R): Product Website Snapshots (Messages for Healthcare Professionals, Hemophilia A without Factor VIII Inhibitors)
Figure 14.10. Hemlibra(R): Product Website Snapshots (Messages for Healthcare Professionals, Hemophilia A with Factor VIII Inhibitors)
Figure 14.11. Hemlibra(R): Product Website Snapshots (Messages for Patients)
Figure 14.12. Hemlibra(R): Presence in Conferences
Figure 15.1. Bispecific Antibody Therapeutics Market, till 2035 (USD Million)
Figure 15.2. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, Current Year and 2035 (USD Million)
Figure 15.3. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, Current Year and 2035 (USD Million)
Figure 15.4. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, Current Year and 2035 (USD Million)
Figure 15.5. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, Current Year and 2035 (USD Million)
Figure 15.6. Bispecific Antibody Therapeutics Market: Distribution by Key Players, Current Year and 2035 (USD Million)
Figure 15.7. Bispecific Antibody Therapeutics Market: Distribution by Geography, Current Year and 2035 (USD Million)
Figure 15.8. AK104 (Akeso Biopharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.9. Blincyto(R) (Amgen) Sales Forecast, Till 2035 (USD Million)
Figure 15.10. Hemlibra(R) (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.11. Kimmtrak(R) (Immunocore) Sales Forecast, Till 2035 (USD Million)
Figure 15.12. Lunsumio(R) (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.13. Nanozora(R) (Taisho Pharmaceutical) Sales Forecast, Till 2035 (USD Million)
Figure 15.14. Rybrevant(TM) (Janssen Research & Development) Sales Forecast, Till 2035 (USD Million)
Figure 15.15. Tecvayli(TM) (Janssen Research & Development) Sales Forecast, Till 2035 (USD Million)
Figure 15.16. Vabysmo(TM) (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.17. AK112 (Akeso Biopharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.18. ALXN1720 (Alexion) Sales Forecast, Till 2035 (USD Million)
Figure 15.19. GEN3013 (Genmab) Sales Forecast, Till 2035 (USD Million)
Figure 15.20. Glofitamab (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.21. LP000 (Linton Pharm) Sales Forecast, Till 2035 (USD Million)
Figure 15.22. M7824 (Merck) Sales Forecast, Till 2035 (USD Million)
Figure 15.23. OMP 305B83 (Mereo BioPharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.24. PF-06863135 (Pfizer) Sales Forecast, Till 2035 (USD Million)
Figure 15.25. ZW25 (Zymeworks) Sales Forecast, Till 2035 (USD Million)
Figure 16.1. Bispecific Antibody Therapeutics: SWOT Analysis
Figure 16.2. Comparison of SWOT Factors: Harvey Ball Analysis

Bispecific Antibodies Market by Therapeutic Area, Mechanism of Action Target Antigen, Antibody Format, Key Geographical Regions and Key Players: Industry Trends and Global Forecasts, Till 2035

Description

Table of Contents

List of Tables

BISPECIFIC ANTIBODIES MARKET OVERVIEW

BISPECIFIC ANTIBODIES MARKET: GROWTH AND TRENDS

BISPECIFIC ANTIBODIES MARKET: KEY INSIGHTS

BISPECIFIC ANTIBODIES MARKET: KEY SEGMENTS

Example Players in the Bispecific Antibodies Market

Primary Research Overview

BISPECIFIC ANTIBODIES MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES

5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES

6. KEY INSIGHTS

7. TECHNOLOGY ASSESSMENT FRAMEWORK

8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS

9. COMPANY PROFILES

10. PARTNERSHIPS AND COLLABORATIONS

11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS

12. CLINICAL TRIAL ANALYSIS

13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES

14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

16. SWOT ANALYSIS

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List of Tables

List of Figures